PALO ALTO, Calif., May 4, 2026
Guardant Health, Inc. has received U.S. Food and Drug Administration (FDA) approval for its Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU™ (vepdegestrant), a targeted therapy co-developed by Arvinas and Pfizer for patients with ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations. This milestone underscores the growing role of precision oncology and non-invasive diagnostics in enabling personalized cancer treatment strategies, marking a significant advancement in molecular diagnostics and targeted therapeutics integration.
Liquid Biopsy Enables Precision Oncology Decisions
The FDA approval of Guardant360® CDx introduces a non-invasive, blood-based testing approach to identify ESR1 mutations, a key mechanism of resistance to endocrine therapy in advanced breast cancer. By enabling detection through a simple blood draw, this technology eliminates the need for invasive tissue biopsies, improving patient accessibility and facilitating real-time treatment decision-making.
The ability to rapidly identify eligible patients for VEPPANU™ therapy represents a major advancement in companion diagnostics, where molecular insights directly guide targeted treatment selection. ESR1 mutations are commonly observed in patients with disease progression following endocrine therapy, making early detection critical for optimizing clinical outcomes. This approval reflects a broader shift toward liquid biopsy platforms as essential tools in modern oncology care, enabling clinicians to monitor disease evolution and resistance mechanisms with greater precision.
Targeted Therapy Integration with Diagnostic Innovation
Advertisement
VEPPANU™ (vepdegestrant) is a PROteolysis TArgeting Chimera (PROTAC) therapy designed to selectively degrade the estrogen receptor, offering a novel treatment option for patients with ESR1-mutated tumors. The integration of Guardant360 CDx as a companion diagnostic ensures that patients most likely to benefit from this therapy are accurately identified, reinforcing the importance of biomarker-driven treatment approaches in oncology.
This approval marks Guardant Health’s third ESR1 companion diagnostic approval and expands the clinical utility of its platform to 26 companion diagnostic indications across multiple tumor types, including lung, breast, and colorectal cancers. The growing adoption of such diagnostics reflects the increasing importance of genomic profiling and targeted therapy alignment in improving patient outcomes and advancing precision medicine.
Regulatory and Market Impact in Oncology Diagnostics
The FDA approval further strengthens Guardant Health’s position as a leader in liquid biopsy and precision diagnostics, with broad coverage across Medicare and commercial payers, reaching more than 300 million covered lives. This extensive coverage enhances accessibility and supports widespread adoption of advanced genomic testing in clinical practice.
The approval also highlights the evolving regulatory landscape, where companion diagnostics and targeted therapies are increasingly co-developed and co-approved, ensuring synchronized availability of both diagnostic tools and therapeutic options. This integrated approach is critical in accelerating drug development timelines and improving treatment precision.
As oncology continues to move toward personalized and data-driven care, the combination of non-invasive diagnostics and targeted therapies is expected to play a central role in shaping the future of cancer treatment. Guardant Health’s latest approval exemplifies how innovation in diagnostics can directly impact therapeutic decision-making and patient outcomes.
Source: Guardant Health press release
